Acta Angiologica, published by VIA MEDICA, is an Open Access journal dedicated to the dynamic field of cardiology and cardiovascular medicine. Since its inception in 1995, this esteemed journal has provided a vital platform for the dissemination of cutting-edge research and innovative medical practices, especially pertinent to vascular health. Being indexed in Scopus, it holds a rank of #352 out of 387 in its category for 2023, positioning it in the 9th percentile among contemporaneous journals. The journal's commitment to scholarly excellence and accessibility is underscored by its embrace of open access publishing, allowing researchers, professionals, and students to engage with vital advancements in the field without financial barriers. With a converged timeline from 2005 to 2024, Acta Angiologica continues to play a crucial role in bridging gaps in cardiovascular knowledge, fostering collaboration across disciplines, and advancing the implementation of preventative and therapeutic strategies in vascular medicine. Located in Gdansk, Poland, the journal is poised to make significant contributions to the cardiovascular research landscape.

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.

ANGIOGENESIS is a prestigious academic journal published by Springer, focusing on the vital field of angiogenesis research, a cornerstone in understanding tumor biology and tissue regeneration. Established in 1997 and continuously evolving, this journal has solidified its reputation, ranking in the Q1 category for Cancer Research, Clinical Biochemistry, and Physiology as of 2023. With an impressive impact factor, it serves as an essential platform for disseminating cutting-edge research findings, critical reviews, and novel methodologies. ANGIOGENESIS is indexed in high-impact databases and exhibits exceptional Scopus ranks—1st in Clinical Biochemistry, 6th in Physiology, and 14th in Cancer Research, underscoring its significant contribution to the scientific community. Although it does not currently offer open access options, it ensures that all articles maintain rigorous peer-review standards to meet the highest academic excellence. Researchers, professionals, and students alike will find ANGIOGENESIS to be an invaluable resource in advancing their knowledge and research in the intricate mechanisms of vascular biology.

Arterial Hypertension is a dedicated Open Access journal published by VIA MEDICA, with the ISSN 2449-6170 and E-ISSN 2449-6162, focusing on the multidisciplinary field of cardiology, endocrinology, and internal medicine. Established in Poland, this journal has been providing researchers and healthcare professionals with accessible, high-quality content since its inception in 1999. With a commitment to advancing knowledge in the management and treatment of arterial hypertension, it publishes significant research findings, clinical trials, and reviews that contribute to improved health outcomes. Though classified in Q4 across various relevant categories, the continuous improvement in its content ensures its relevance in an evolving medical landscape. Designed to facilitate collaboration and innovation, Arterial Hypertension serves as a crucial resource for anyone invested in cardiovascular health, encouraging open dialogue and dissemination of vital research within the scientific community.

NEPHROLOGY is a leading academic journal published by Wiley, dedicated to advancing research and discussions in the fields of Nephrology and Medicine. With an ISSN of 1320-5358, this journal has consistently demonstrated its significance and impact, reflecting a Q2 category ranking in both Medicine (miscellaneous) and Nephrology as of 2023. Covering a comprehensive range of topics since its inception in 1995, NEPHROLOGY provides a vital platform for researchers, practitioners, and students alike to explore the latest advancements, innovative treatments, and diverse challenges within the field. Although it does not operate under an open access model, the journal remains highly regarded, with a commendable Scopus rank of #27 out of 81 in Nephrology, positioning it in the 67th percentile among its peers. Located in the United Kingdom, NEPHROLOGY invites submissions that push the boundaries of knowledge, ultimately striving to enhance the understanding of renal health and disease.

Diabetes & Vascular Disease Research is a leading academic journal dedicated to advancing the understanding and treatment of cardiovascular and metabolic diseases, particularly diabetes. Published by SAGE Publications Ltd in the United Kingdom, this journal serves as a key resource for researchers, clinicians, and students seeking to explore the intricate relationship between diabetes and vascular health. With an impressive Impact Factor and ranked in the Q2 quartile in prominent categories such as Cardiology, Endocrinology, and Internal Medicine, the journal provides a platform for high-quality, peer-reviewed research. Covering a broad range of topics from pathophysiology to therapeutic innovations, Diabetes & Vascular Disease Research plays a vital role in shaping contemporary discourse in the field. With contributions from leading experts and a commitment to disseminating valuable findings, this journal is a must-read for anyone involved in the fight against vascular complications arising from diabetes.

HEART AND VESSELS is a prominent peer-reviewed journal published by SPRINGER, dedicated to advancing the fields of cardiology and cardiovascular medicine. With its ISSN 0910-8327 and E-ISSN 1615-2573, this esteemed journal encompasses a broad range of topics pertinent to heart health, vascular function, and associated therapies, making it an essential resource for researchers, clinicians, and healthcare professionals alike. Based in Japan and operating since 1985, HEART AND VESSELS has consistently maintained a Q2 ranking in the 2023 category quartiles, highlighting its relevance and impact in the cardio domain. Although it does not offer open access, the journal ensures high-quality publications that contribute significantly to the academic and clinical understanding of cardiovascular health. With over three decades of continuous scholarly contribution, HEART AND VESSELS serves as a vital platform for disseminating cutting-edge research and fostering innovative practices in the management of cardiovascular diseases.

The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.

International Heart Journal, published by INT HEART JOURNAL ASSOC, serves as a pivotal platform for research and discourse in the fields of cardiology and cardiovascular medicine. With its ISSN 1349-2365 and E-ISSN 1349-3299, this esteemed journal is based in Japan and is located at the University of Tokyo, Graduate School of Medicine, Department of Cardiovascular Medicine. Since its inception in 2005, International Heart Journal has blossomed into a respected publication with an impact factor that signifies its growing relevance, ranking in the Q3 category of both cardiology and miscellaneous medicine as of 2023. This journal not only disseminates vital research findings but also fosters collaboration among researchers and healthcare professionals. Notable for its Open Access options, it ensures the availability of its content to a broader audience, thereby enhancing knowledge transfer and innovation in cardiovascular care. With an ongoing commitment to improve clinical practice and patient outcomes, the journal continues to be an essential resource for those dedicated to advancing the understanding of heart health and disease.

Rational Pharmacotherapy in Cardiology, published by the SOC CARDIOLOGY RUSSIAN FEDERATION, stands as a crucial platform for advancing knowledge in the field of cardiology and pharmacology. Established as an Open Access journal in 2005, it allows for unrestricted access to research findings, fostering collaboration among researchers, clinicians, and students. The journal, with its ISSN 1819-6446 and E-ISSN 2225-3653, focuses on the intersection of rational pharmacotherapy and cardiovascular medicine, aiming to enhance treatment strategies and patient outcomes through evidence-based studies. Though currently positioned in the Q4 category in both cardiology and pharmacology rankings, its ongoing commitment to rigorous peer review and scholarly research ensures its relevance and growth in the scientific community. With a unique address in Moscow, Russia, the journal seeks to serve as a valuable resource for those dedicated to improving cardiovascular health and therapeutic practices worldwide, making it an essential read for professionals keen on the latest trends and discoveries in this vital area of medicine.